dc.contributor.author
Han, Bing
dc.contributor.author
Molins López-Rodó, Laureano
dc.contributor.author
He, Yangyi
dc.contributor.author
Viñolas Segarra, Núria
dc.contributor.author
Sánchez Lorente, David
dc.contributor.author
Boada, Marc
dc.contributor.author
Guirao Montes, Àngela
dc.contributor.author
Díaz Sánchez, Tania
dc.contributor.author
Martinez, Daniel
dc.contributor.author
Ramirez, José
dc.contributor.author
Moisés, Jorge
dc.contributor.author
Acosta Plasencia, Melissa
dc.contributor.author
Monzó Planella, Mariano
dc.contributor.author
Marrades Sicart, Ramon Ma.
dc.contributor.author
Navarro Ponz, Alfons
dc.date.issued
2022-10-13T14:49:38Z
dc.date.issued
2022-10-13T14:49:38Z
dc.date.issued
2022-06-27
dc.date.issued
2022-10-13T14:49:39Z
dc.identifier
https://hdl.handle.net/2445/189870
dc.description.abstract
In resected non-small cell lung cancer (NSCLC), post-surgical recurrence occurs in around 40% of patients, highlighting the necessity to identify relapse biomarkers. An analysis of the extracellular vesicle (EV) cargo from a pulmonary tumor-draining vein (TDV) can grant biomarker identification. We studied the pulmonary TDV EV-miRNAome to identify relapse biomarkers in a two-phase study (screening and validation). In the screening phase, a 17-miRNA relapse signature was identified in 18 selected patients by small RNAseq. The most expressed miRNA from the signature (EV-miR-203a-3p) was chosen for further validation. Pulmonary TDV EV-miR-203a-3p was studied by qRT-PCR in a validation cohort of 70 patients, where it was found to be upregulated in relapsed patients (p = 0.0194) and in patients with cancer spread to nearby lymph nodes (N+ patients) (p = 0.0396). The ROC curve analysis showed that TDV EV-miR-203a-3p was able to predict relapses with a sensitivity of 88% (AUC: 0.67; p = 0.022). Moreover, patients with high TDV EV-miR-203a-3p had a shorter time to relapse than patients with low levels (43.6 vs. 97.6 months; p = 0.00703). The multivariate analysis showed that EV-miR-203a-3p was an independent, predictive and prognostic post-surgical relapse biomarker. In conclusion, pulmonary TDV EV-miR-203a-3p is a promising new relapse biomarker for resected NSCLC patients.
dc.format
application/pdf
dc.relation
Reproducció del document publicat a: https://doi.org/10.3390/ijms23137138
dc.relation
International Journal of Molecular Sciences, 2022, vol. 23, num. 13, p. 7138
dc.relation
https://doi.org/10.3390/ijms23137138
dc.rights
cc-by (c) Han, Bing et al., 2022
dc.rights
https://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
dc.subject
Marcadors tumorals
dc.subject
Càncer de pulmó
dc.title
Characterization of the MicroRNA Cargo of Extracellular Vesicles Isolated from a Pulmonary Tumor-Draining Vein Identifies miR-203a-3p as a Relapse Biomarker for Resected Non-Small Cell Lung Cancer.
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion